Brief: UCB: ORCHESTRA Minzasolmin Study Doesn't Meet Primary Or Secondary Clinical Endpoints

UCB SA

16/12/2024 18:04

(Repeats to widen distribution. No change to text.)
       Dec 16 (Reuters) - Ucb SA  UCB.BR :
    * UCB ANNOUNCES ORCHESTRA MINZASOLMIN STUDY DID NOT MEET
PRIMARY
OR SECONDARY CLINICAL ENDPOINTS
    * IS PROGRESSING UCB7583, CURRENTLY UNDER INVESTIGATION FOR
PREVENTING EXTRACELLULAR ALPHA-SYNUCLEIN SPREAD
    * IS PROGRESSING GLOVADALEN (UCB0022), SMALL MOLECULE,
DESIGNED TO
ENHANCE POTENCY OF DOPAMINE 'WHEN AND WHERE NEEDED' TO ACTIVATE
DOPAMINE D1 RECEPTOR
    * HAS INITIATED MEASURES TO TERMINATE EXTENSION PHASE OF
ORCHESTRA
PROGRAM

Source text: https://shorturl.at/VM4gU
Further company coverage:  UCB.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))